Fiche publication


Date publication

janvier 2016

Journal

JAMA oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr LEPAGE Côme


Tous les auteurs :
Boige V, Vincent M, Alexandre P, Tejpar S, Landolfi S, Le Malicot K, Greil R, Cuyle PJ, Yilmaz M, Faroux R, Matzdorff A, Salazar R, Lepage C, Taieb J, Laurent-Puig P

Résumé

Previous pharmacogenetic studies have shown the prognostic impact of several rare dihydropyrimidine dehydrogenase gene (DPYD) variants on fluorouracil-related adverse events (fluorouracil AEs). However, conflicting results highlight the need for prospective validation in large, homogeneous patient populations uniformly treated with current standard combination therapies used in colon cancer (CC).

Référence

JAMA Oncol. 2016 Jan;: